StreetInsider.com News Articles

Research conducted at University of Michigan published in Anesthesia & Analgesia Practice demonstrates GE HealthCare End-tidal Control software may help to reduce fresh gas flow

Fri, 16 Oct 2026 08:47:00 -0400

Study of nearly 13,000 adult general anesthesia cases found clinician use of End-tidal Control softwarei at a large multisite academic medical center was associated with a reduction in fresh gas flow, sevoflurane consumption and estimated CO2 equivalents during maintenance of anesthesia
End-tidal Control software automatically adjusts fresh gas flow concentrations of O2 and anesthetic agent concentrations to maintain targets set by the clinician, and, as one study shows, with more accuracy versus manual control for safeii, low-flowiii anesthesia

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced the publication of research conducted at the University of Michiganiv evaluating the

Research conducted at University of Michigan published in Anesthesia & Analgesia Practice demonstrates GE HealthCare End-tidal Control software may help to reduce fresh gas flow

Fri, 16 Oct 2026 08:47:00 -0400

Study of nearly 13,000 adult general anesthesia cases found clinician use of End-tidal Control softwarei at a large multisite academic medical center was associated with a reduction in fresh gas flow, sevoflurane consumption and estimated CO2 equivalents during maintenance of anesthesia
End-tidal Control software automatically adjusts fresh gas flow concentrations of O2 and anesthetic agent concentrations to maintain targets set by the clinician, and, as one study shows, with more accuracy versus manual control for safeii, low-flowiii anesthesia

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced the publication of research conducted at the University of Michiganiv evaluating the

GE HealthCare cyclotron wins CE Mark, adds Copper-64 support

Thu, 15 Oct 2026 08:01:21 -0400

GE HealthCare (Nasdaq: GEHC) announced that its MINItrace Magni cyclotron has received CE Mark certification and that its PETtrace Solid Target Platform now supports Copper-64 production, according to a company press release.

The MINItrace Magni is a compact, self-shielded cyclotron designed for in-house production of PET radioisotopes, including Fluorine-18, Carbon-11, Oxygen-15 and Nitrogen-13. The system features a three-click workflow and automated functions such as auto-tuning, which handles beam preparation and target irradiation. The CE Mark allows the device to be marketed in European markets.

The PETtrace Solid Target Platform, which was introduced in 2022 with Gallium-68 support and expanded to Zirconium-89 in

GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68

Thu, 15 Oct 2026 08:00:00 -0400

MINItrace Magni combines a compact, self-shielded design with automated operation to help healthcare providers establish and expand local production of radioisotopes used in PET tracers

Copper-64 expands the PETtrace Solid Target Platform beyond Gallium-68, supporting research in both copper-based imaging agents and the potential Copper-64/Copper-67 theranostic pair

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced that its MINItrace Magni cyclotron has achieved CE Mark and that its PETtrace Solid Target Platform is expanding beyond Gallium-68 with support for Copper-64 (⁶⁴Cu) production. Together, the developments reflect the company’s focus on helping institutions build the production capabilities behind their

GE HealthCare's MINItrace™ Magni achieves CE Mark; Copper-64 expands PETtrace™ Solid Target Platform beyond Gallium-68

Thu, 15 Oct 2026 08:00:00 -0400

MINItrace Magni combines a compact, self-shielded design with automated operation to help healthcare providers establish and expand local production of radioisotopes used in PET tracers

Copper-64 expands the PETtrace Solid Target Platform beyond Gallium-68, supporting research in both copper-based imaging agents and the potential Copper-64/Copper-67 theranostic pair

GE HealthCare (GEHC) spreader of 2K contracts of October 68 and 72 calls, share price up 2.9%

Mon, 12 Oct 2026 15:27:09 -0400

GE HealthCare (NASDAQ: GEHC) 30-day option implied volatility is at 38; compared to its 52-week range of 24 to 44 with a focus a spreader of 2K contracts of October 68 and 72 calls, share price up 2.9%.

GE HealthCare to announce third quarter 2026 results on October 28, 2026

Wed, 07 Oct 2026 08:00:00 -0400

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2026 financial results before the market opens on Wednesday, October 28, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading

GE HealthCare to announce third quarter 2026 results on October 28, 2026

Wed, 07 Oct 2026 08:00:00 -0400

About GE HealthCare Technologies Inc.

GE HealthCare is a leading

Barclays Starts GE HealthCare (GEHC) at Overweight

Tue, 06 Oct 2026 16:24:47 -0400

Barclays analyst Matt Miksic initiates coverage on GE HealthCare (NASDAQ: GEHC) with a Overweight rating and a price target of $85.00.

For an analyst ratings summary and ratings history on GE HealthCare click here. For more ratings news on GE HealthCare click here.

Shares of GE HealthCare closed at $65.74 yesterday.

Needham Reiterates Buy Rating on GE HealthCare (GEHC)

Mon, 05 Oct 2026 09:43:30 -0400

Needham analyst David Saxon reiterated a Buy rating and $93.00 price target on GE HealthCare (NASDAQ: GEHC).

The analyst comments "This morning, GEHC announced an agreement to acquire Sofie Biosciences for $945M in cash. The deal is expected to close in 1H27 and should be accretive to GEHC's revenue growth, operating margin, and EPS in the first full year. We believe the deal should allow GEHC to vertically integrate its radiopharmaceuticals portfolio and also adds a phase 3 asset to the pipeline. We reiterate our Buy rating."

For an analyst ratings summary and ratings history on GE HealthCare click here. For

RBC Capital Reiterates Outperform Rating on GE HealthCare (GEHC)

Mon, 05 Oct 2026 09:31:45 -0400

RBC Capital analyst Shagun Singh reiterated an Outperform rating and $80.00 price target on GE HealthCare (NASDAQ: GEHC).

The analyst comments "This morning (10/5), GEHC announced a definitive agreement to acquire SOFIE Biosciences, a U.S. CMO focused on radiopharmaceutical end-markets, from Trilantic North America for $945MM in cash. The deal brings 15 U.S. manufacturing sites with 21 cyclotrons, a CDMO facility for theranostics, and U.S. rights to FAPI-74, which is a Phase III pan-cancer PET radiotracer for which GEHC already holds ex-U.S. rights. The transaction is expected to close in 1H'27 and be accretive to revenue growth (expected to grow low-double

GE HealthCare to buy SOFIE Biosciences for $945M in cash

Mon, 05 Oct 2026 08:00:41 -0400

GE HealthCare (Nasdaq: GEHC) has agreed to acquire SOFIE Biosciences, a U.S.-based contract manufacturing organization (CMO) for positron emission tomography (PET) radiopharmaceuticals, from Trilantic North America for $945 million in cash.

The transaction is expected to close in the first half of 2027, subject to regulatory approvals and other closing conditions. Upon closing, SOFIE Biosciences will become part of GE HealthCare's Pharmaceutical Diagnostics (PDx) segment.

SOFIE Biosciences operates 15 CMO sites across the U.S., running 21 cyclotrons, along with a theranostics-focused Contract Development and Manufacturing Organization site. The acquisition gives GE HealthCare a manufacturing presence in the time-sensitive final stage of U.S.

GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.

Mon, 05 Oct 2026 08:00:00 -0400

Broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas
Pharmaceutical Diagnostics (PDx) continues to partner with other established Contract Manufacturing Organizations (CMOs) to drive and expand patient access to its radiopharmaceutical portfolio, while SOFIE Biosciences continues to supply PET products from other leading radiopharmaceutical providers
Provides U.S. rights to FAPI-74, a Phase III pipeline PET radiotracer with pan-cancer imaging potential, aiming to be among the first-to-launch in a large and fast-growing market1

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced a

GE HealthCare to Acquire SOFIE Biosciences, Establishing a 'Final Mile' Footprint for PET Radiopharmaceutical Supply in the U.S.

Mon, 05 Oct 2026 08:00:00 -0400

Broadens GE HealthCare's footprint in the U.S. radiopharmaceutical industry, drives patient access to F18 labeled Positron Emission Tomography (PET) radiopharmaceuticals and enhances exposure to new high-growth areas
Pharmaceutical Diagnostics (PDx) continues to partner with other established Contract Manufacturing Organizations (CMOs) to drive and expand patient access to its radiopharmaceutical portfolio, while SOFIE Biosciences continues to supply PET products from other leading radiopharmaceutical providers
Provides U.S. rights to FAPI-74, a Phase III pipeline PET radiotracer with pan-cancer imaging potential, aiming to be among the first-to-launch in a large and fast-growing market1

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced a

GE HealthCare (GEHC) Declares $0.04 Quarterly Dividend; 0.2% Yield

Tue, 22 Sep 2026 17:41:34 -0400

GE HealthCare (NASDAQ: GEHC) declared a quarterly dividend of $0.04 per share, or $0.16 annualized.

The dividend will be payable on November 13, 2026, to stockholders of record on October 23, 2026, with an ex-dividend date of October 22, 2026.

The annual yield on the dividend is 0.2 percent.

For a dividend history and other dividend-related data on GE HealthCare (GEHC) click here.

GE HealthCare announces cash dividend increase for third quarter of 2026

Tue, 22 Sep 2026 17:25:00 -0400

CHICAGO--(BUSINESS WIRE)-- The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.04 per share of Common Stock for the third quarter of 2026, an increase of 14% from the previous quarter. The dividend will be payable on November 13, 2026, to all shareholders of record as of October 23, 2026.

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130

GE HealthCare announces cash dividend increase for third quarter of 2026

Tue, 22 Sep 2026 17:25:00 -0400

About GE HealthCare Technologies Inc.

Form 8-K GE HealthCare Technologi For: Sep 22

Tue, 22 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260922/27091103.html

GE HealthCare names AT&T CFO Pascal Desroches to its board

Tue, 22 Sep 2026 16:05:13 -0400

GE HealthCare (Nasdaq: GEHC) announced the appointment of Pascal Desroches to its Board of Directors, effective January 4, 2027, according to a company press release.

Desroches currently serves as Senior Executive Vice President and Chief Financial Officer of AT&T (NYSE: T), a position he has held since 2021. He plans to retire from AT&T on December 31, 2026.

Prior to his role at AT&T, Desroches served as CFO of WarnerMedia following AT&T's acquisition of Time Warner in 2018, overseeing financial operations, global real estate, and technology across HBO, Turner Broadcasting, and Warner Bros. As CFO of Turner Broadcasting, he was involved in

GE HealthCare names AT&T CFO Pascal Desroches to its board

Tue, 22 Sep 2026 16:05:13 -0400

GE HealthCare (Nasdaq: GEHC) announced the appointment of Pascal Desroches to its Board of Directors, effective January 4, 2027, according to a company press release.

Desroches currently serves as Senior Executive Vice President and Chief Financial Officer of AT&T (NYSE: T), a position he has held since 2021. He plans to retire from AT&T on December 31, 2026.

GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors

Tue, 22 Sep 2026 16:05:00 -0400

CHICAGO--(BUSINESS WIRE)-- GE HealthCare (Nasdaq: GEHC) today announced the appointment of Pascal Desroches, Senior Executive Vice President and Chief Financial Officer (CFO) of AT&T (NYSE: T), a Fortune 50 company, to its Board of Directors, effective January 4, 2027. Mr. Desroches brings more than 30 years of leadership experience across finance, governance, and large-scale technology and digital transformation.

“Pascal is a highly respected executive and accomplished financial leader whose experience spans corporate strategy, capital deployment, and investor engagement,” said H. Lawrence Culp, Jr., Chairman of the Board of Directors, GE HealthCare. “His perspective will further strengthen our

GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors

Tue, 22 Sep 2026 16:05:00 -0400

GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors

Tue, 22 Sep 2026 16:05:00 -0400

GE HealthCare appoints veteran finance executive Pascal Desroches to Board of Directors

Tue, 22 Sep 2026 16:05:00 -0400

Needham Starts GE HealthCare (GEHC) at Buy

Tue, 22 Sep 2026 06:33:16 -0400

Needham analyst David Saxon initiates coverage on GE HealthCare (NASDAQ: GEHC) with a Buy rating and a price target of $93.00.

The analyst comments "Our Bull-Bear analysis of GEHC suggests shares are largely pricing in a Bear case, which creates an attractive risk/reward. Further, given GEHC's capital book-to-bill's correlation with capital growth outlook, we expect AIS growth to accelerate in 2027, which should serve as a source of upside to Street models, which only reflect PCS growth improving. Given GEHC's financial profile is similar to our large-cap peer group median, we expect there to be modest multiple expansion. As a result,